Eli Lilly Leverages GLP-1 Portfolio and Stable Finances to Sustain Long-Term Growth
Eli Lilly and Company (NYSE: LLY) remains positioned for durable expansion, supported by its expanding portfolio of glucagon-like peptide-1 (GLP-1) therapies and consistent financial performance. The Indianapolis-based pharmaceutical manufacturer is currently highlighted among the “10 Best Rising Dividend Stocks to Buy Now,” underlining investor confidence in the firm’s ability to balance innovation with shareholder returns. […]